PEER-REVIEWED PUBLICATIONS 

PUBLISHED 

1. Sadashiv, Sharma, P., Dwivedi, S. Tiwari, S., Singh, PK., Pal, A., et al. Micro (mi) RNA and Diabetic Retinopathy. Indian J Clin Biochem 2022;37(3):267-274.  

1. Singh PK, Bhatt MLB, Singh P, Rath SK, Dalela D, Goel MM. CASC5 is a potential cancer-testis gene in human urinary bladder transitional cell carcinoma. Drug Discovery & therapeutics 2021;15(6):331-336.  

1. Singh PK, Bhatt MLB, Singh P, Rath SK, Dalela D, Goel MM. Frequent expression of a novel cancer testis antigen, protein kinase human monopolar spindle 1 (hMps1/TTK) in human urinary bladder transitional cell carcinoma. Drug Discovery & therapeutics 2021;15(4):204-209.  

1. Sadashiv, Modi A, Khokhar, M, Sharma, P, Joshi R, Mishra SS, Bharshankar R, Tiwari S, Singh PK, Bhosale VV, Negi MPS. Leptin DNA methylation and its association with metabolic risk factors in North – West Indian obese population. Journal of Obesity & Metabolic Syndrome. 2021;30(3):59-64.  

1. Srivastava AK, Singh PK, Singh D, Dalela D, Rath SK, Bhatt ML. Clinical utility of urinary soluble Fas in screening for bladder cancer. Asia-Pacific J of Clinical Oncology 2016;12(2):e215-21.  

1. Singh PK, Srivastava AK, Rath SK, Dalela D, Goel MM, Bhatt ML. Expression and clinical significance of Centrosomal protein 55 (CEP55) in human urinary bladder transitional cell carcinoma. Immunobiology 2015;220(1):103-108.  

1. Singh PK, Srivastava AK, Dalela D, Rath SK, Goel MM, Bhatt ML. Frequent Expression of zinc-finger protein ZNF165 in human urinary bladder transitional cell carcinoma. Immunobiology 2015;220(1):68-73. 

1. Srivastava AK, Singh PK, Rath SK, Dalela D, Goel MM, Bhatt ML. Appraisal of diagnostic ability of UCA1 as a biomarker of carcinoma urinary bladder. Tumor Biology 2014;35(11):11435-42.  

1. Srivastava AK, Singh PK, Singh D, Dalela D, Rath SK, Goel MM, Bhatt ML. Evaluation of urinary XIAP as a diagnostic biomarker of carcinoma of urinary bladder. Tumor Biol 2014;35(8):8243-8.  

1. Singh PK, Srivastava AK, Dalela D, Rath SK, Goel MM, Bhatt ML. Expression of PDZ-Binding Kinase/T-LAK Cell-Originated Protein Kinase (PBK/TOPK) in human urinary bladder transitional cell carcinoma. Immunobiology 2014;219(6):469-474.  

1. Singh PK, Srivastava AK, Dalela S, Rath SK, Bhatt ML. Quantitative analysis of telomerase activity in exfoliated human urothelial cells of transitional cell carcinoma of urinary bladder. IJHBR 2014;2(2):87-94.  

1. Srivastava AK, Singh PK, Srivastava K, Singh D, Dalela D, Rath SK, Bhatt ML. Diagnostic role of Survivin in urinary bladder cancer. Asian Pac J Cancer Prev. 2013;14(1):81-5.  

1. Gupta S, Pant MC, Husain N, Sundar S, Singh PK. Primary intraparenchymal brain melanoma: a case report. J Radiosurg SBRT. 2012;1(4):339-341.  

1. Gupta S, Singh PK, Bhatt ML, Pant MC, Gupta R, Negi MPS.  Efficacy of granulocyte colony stimulating Factor (G-CSF) as a secondary prophylaxis along with full-Dose chemotherapy following a prior cycle of febrile neutropenia. BioScience Trends. 2010; 4(5):273-278.  

1. Gupta S, Singh PK, Bhatt ML, Pant MC, Sundar S, Verma J, Paul S, Kumar D, Shah A, Gupta R, Negi MPS. Clinical benefits of two different dosing schedules of recombinant human erythropoietin in anemic patients with advanced head and neck cancer. BioScience Trends. 2010;4(5):267-272.  

1. Chhavi, Saxena M, Negi MPS, Singh S, Singh PK, Singh U, Bhatt ML. DNA content can improve the detection and prognosis of carcinoma of the cervix. BioScience Trends. 2010; 4(3):103-9.  

1. Gupta S, Singh PK, Bisth SS, Bhatt MLB, Pant M, Gupta R, Gupta D, Negi MPS. Role of recombinant human erythropoietin in patients with advanced cervical cancer treated “by Chemoradiotherapy”. Cancer biology & therapy 2009;8(1):9-13.  

PEER-REVIEWED ABSTRACTS AS JOURNAL SUPPLEMENTS 

1. Singh PK, Srivastava AK, Singh P, Khan H, Dalela D, Bhatt MLB, Rath SK. Identification of Novel Biomarker of Human Urinary Bladder Cancer. J Cancer Res Ther Suppl 2012 Jan; 8(1): S9. 

1. Singh PK, Srivastava A, Singh P, Singh D, Dalela D, Goel M, Gupta S, Negi MPS, Bhatt M, Rath S. Diagnostic and prognostic potential of CK20 gene expression in patients with transitional-cell carcinoma of the urinary bladder. Eur J Cancer Suppl 2011; 9(1):4-5.  

1. Singh PK, Srivastava A, Singh P, Singh D, Dalela D, Goel M, Gupta S, Negi MPS, Bhatt M, Rath S. Clinical utility of survivin gene expression in patients with transitional-cell carcinoma of the urinary bladder. Eur J Cancer Suppl 2011; 9(1):14-15. 

1. Srivastava AK, Singh PK, Singh P, Singh D, Bhatt MLB, Dalela D, Goel MM, Gupta S, Negi MPS, Rath SK. Clinical experience with UCA1 as a biomarker for non-muscular invasive bladder cancer. Eur Urol Suppl 2011; 10(2):74. 

1. Gupta S, Singh PK, Bhatt ML, Pant MC, Sundar S, Verma J, Negi MPS. Clinical benefits of Epoetin beta in patients with advanced stage hormone refractory prostate cancer. Eur Urol Suppl 2011;10(2):337.  

1. Gupta S, Singh PK, Khan H, Bhatt M, Pant MC, Sundar S, Verma J, Negi M. Positive response to bevacizumab with selective bladder conservation in recurrent and metastatic bladder cancer. Eur Urol Suppl 2011; 10(2):211. 

CONTRIBUTIONS TO NCBI (NATIONAL CENTRE FOR BIOTECHNOLOGY INFORMATION) 

Contributed 8 samples and one series of microarray data to Gene Expression Omnibus (GEO) (Series Accession No: GSE23732: Whole genome expression data from human urinary bladder cancer) on Feb 22, 2012.